Analysis of the Funding Status and Research Focus in Field of Anti-Tumor Drugs Pharmacology in Projects Funded byNational Natural Science Foundation of China from 2015 to 2024
- VernacularTitle:2015～2024年国家自然科学基金抗肿瘤药物药理研究领域项目申请资助情况和关注热点分析
- Author:
Yue LIU
1
;
Nan ZHENG
;
Li-wei HAN
Author Information
- Publication Type:Journal Article
- Keywords: national natural science foundation of chi-na; pharmacology; anti-tumor drugs pharmacology; a-nalysis of projects; research fields; scientific issue
- From: Chinese Pharmacological Bulletin 2025;41(12):2201-2211
- CountryChina
- Language:Chinese
- Abstract: Aim To delineate the research hotspots in the National Natural Science Foundation of China(NS-FC)in the field of Anti-Tumor Drugs Pharmacology(application code H3505)from 2015 to 2024,and to identify common deficiencies in grant applications,with the aim of promoting high-quality development of original anti-tumor targets and innovative drug research in China.Methods We compiled NSFC data for 2015-2024 on General Program,Young Scientist Fund and Fund for Less Developed Regions in the field of Anti-Tumor Drugs Pharmacology,examining appli-cation and funding trends.A multidimensional analysis was conducted on project topics,disciplinary hot-spots,interdisciplinary integration,and the adoption of emerging technologies and methodologies.Results A total of 798 projects were funded,with direct alloca-tions of RMB 293.52 million.Funded research con-centrated on drug resistance,novel target discovery,immunotherapy,and the tumor microenvironment;key mechanisms included programmed cell death,immune checkpoints,and metabolic reprogramming;and ad-vanced approaches-microbiome and multi-omics inte-gration,organoid models,and AI-assisted target min-ing-were widely adopted.Unfunded proposals most often suffered from insufficient innovation,weak pre-liminary data,and poorly defined scientific questions.Conclusions Antitumor pharmacology in China has transitioned from nonspecific cytotoxic strategies to pre-cision,multi-modal approaches exemplified by nucleic acid drugs,immunotherapies,and multitarget inhibi-tors.Continued emphasis on original target discovery,mechanistic innovation,and interdisciplinary,technol-ogy-driven research will be critical to advancing the field.
